CID
Lerma de Villada, Mexico
CID
Lerma de Villada, Mexico

Time filter

Source Type

SEATTLE--(BUSINESS WIRE)--In a unanimous vote, the Board of Trustees of the Center for Infectious Disease Research (CID Research) appointed John Aitchison, professor and chief science officer, as president and director. Aitchison will amplify the world recognition of the Center’s research and vision. “CID Research is renowned for cutting-edge research with an impact that will increase exponentially with John, a leader who cares deeply about the humanitarian side of science along with the success of the Center and the people who work here,” says Board of Trustees Chairman Irwin Goverman. “We are excited about his vision for the future.” Aitchison has held key leadership roles at CID Research since 2011. He is internationally recognized as a pioneer of the systems biology approach combining computational and high-throughput biology, most recently applying this to infectious disease. Aitchison’s activity in the scientific community is extensive, including teaching, editorial and advisory roles with international universities, journals, research institutes and biotech companies. “I am confident in John’s vision and ability to ensure our Center continues its forty-year tradition of innovation and impact in infectious disease research,” says Kenneth Stuart, CID Research founder and professor. “I am honored by the Board’s confidence and for the opportunity to continue working alongside outstanding colleagues at CID Research,” says Aitchison. “Our mission has never been more critical and the technologies available to us today enable new approaches never before thought possible. I am sure these methods will lead to breakthroughs that will save lives, relieve suffering, strengthen societies and expand economies across the globe.” Aitchison begins his new role at CID Research at a time of unparalleled progress in the fight against infectious diseases just as issues of awareness and funding of pioneering scientific research become more critical than ever. ABOUT THE CENTER FOR INFECTIOUS DISEASE RESEARCH CID Research is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our research is the foundation for new drugs, vaccines and diagnostics that benefit those who need our help most: the 14 million people who will otherwise die each year from infectious diseases, including malaria, HIV/AIDS and tuberculosis. Founded in 1976, the Center partners with key international collaborators and focuses on discoveries that will save lives. For more information, visit www.cidresearch.org.


HOUSTON, April 26, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. EDT in Boston, Massachusetts. A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.


News Article | May 4, 2017
Site: www.PR.com

Powerstone donates $75,500 to PCRF at Reaching for the Cure Event. The Pediatric Cancer Research Foundation is celebrating the events 19th year. Thousands attend. Irvine, CA, May 04, 2017 --( Jeri Wilson, PCRF Executive Director had this to say: "We consider Powerstone to be a leader in the fight to find a cure for pediatric cancer. They provide volunteer team members as well as financial support and a true spirit of giving that sets the bar very high.” She added: “At Reaching for the Cure Run and Ride, Team Powerstone makes curing cancer fun, while raising money year round with their company and vendors. These children need our help, they may only be 1% of the oncology population, but they are 100% of our future. Let’s give these families hope, so that their children can live out their dreams.” This year Powerstone is excited to name the following Diamond Sponsors who donated a minimum of $4,250 and include Antis Roofing & Waterproofing, Animal Pest Management, Nordic Security Services, James LeCourt Plumbing, O’Connell Landscape Maintenance, Park West Landscape Management, Fontaine Weatherproofing, and The Perry Law Firm. About PCRF The Pediatric Cancer Research Foundation holds special events throughout the year. For more information call the PCRF office at 949-859-6312 or visit www.pcrf-kids.org. Since its founding in 1982, PCRF has partnered with businesses, foundations, and individuals and has raised over $30 million toward the ultimate goal of ending pediatric cancers. About Powerstone Known for its exceptional service, Powerstone is a recognized leader and one of the largest property management firms in Southern California. Since 1993 Powerstone has served the CID industry (common interest development) with integrity, professionalism and expertise, including three on-staff CPA’s. From professional business planning, governance, and community management, to modern yet easy to use customized websites and on-line services, Powerstone provides homeowner associations complete and unparalleled service including customized Community Planning. Powerstone believes that every association deserves the chance to attain their vision for their property and that’s why we created the best combination of people and technology to not only better serve, but also to better achieve. For more information, go to www.Powerstonepm.com Irvine, CA, May 04, 2017 --( PR.com )-- Powerstone Property Management Inc. a full service Orange County California based property management firm announced today that $75,500 was raised in support of the Pediatric Cancer Research Foundation (PCRF) which recently hosted their Reaching for the Cure Event. The 19th Annual 10K Run, 5K Run/Walk, 1K Kids' Fun Run & Bike Tour event raised over $565,000 in total contributions. It is recognized as one of OC’s favorite weekend family events. It was held at Irvine Valley College on March 25th and 26th and was attended by over 5,000 people. Powerstone, for the sixth year in a row, raised the largest amount for a Corporate Champion team. “Team Powerstone is very excited to be a part of this great event. And, this year thanks in large part to our Diamond Sponsors, we broke our own record,” says Rene’ Decker, CEO of Powerstone, who adds: “Once again I’d like to thank our team lead by Kendrah Kay for the outstanding job she does in getting sponsors and raising the level of excitement for the event. I honestly feel like this makes a big difference in reaching the cure. We’re very proud to be part of such a great cause.”Jeri Wilson, PCRF Executive Director had this to say: "We consider Powerstone to be a leader in the fight to find a cure for pediatric cancer. They provide volunteer team members as well as financial support and a true spirit of giving that sets the bar very high.” She added: “At Reaching for the Cure Run and Ride, Team Powerstone makes curing cancer fun, while raising money year round with their company and vendors. These children need our help, they may only be 1% of the oncology population, but they are 100% of our future. Let’s give these families hope, so that their children can live out their dreams.”This year Powerstone is excited to name the following Diamond Sponsors who donated a minimum of $4,250 and include Antis Roofing & Waterproofing, Animal Pest Management, Nordic Security Services, James LeCourt Plumbing, O’Connell Landscape Maintenance, Park West Landscape Management, Fontaine Weatherproofing, and The Perry Law Firm.About PCRFThe Pediatric Cancer Research Foundation holds special events throughout the year. For more information call the PCRF office at 949-859-6312 or visit www.pcrf-kids.org. Since its founding in 1982, PCRF has partnered with businesses, foundations, and individuals and has raised over $30 million toward the ultimate goal of ending pediatric cancers.About PowerstoneKnown for its exceptional service, Powerstone is a recognized leader and one of the largest property management firms in Southern California. Since 1993 Powerstone has served the CID industry (common interest development) with integrity, professionalism and expertise, including three on-staff CPA’s. From professional business planning, governance, and community management, to modern yet easy to use customized websites and on-line services, Powerstone provides homeowner associations complete and unparalleled service including customized Community Planning. Powerstone believes that every association deserves the chance to attain their vision for their property and that’s why we created the best combination of people and technology to not only better serve, but also to better achieve. For more information, go to www.Powerstonepm.com Click here to view the list of recent Press Releases from PowerStone Property Management


News Article | May 4, 2017
Site: www.24-7pressrelease.com

IRVINE, CA, May 04, 2017 /24-7PressRelease/ -- Powerstone Property Management Inc. a full service Orange County California based property management firm announced today that $75,500 was raised in support of the Pediatric Cancer Research Foundation (PCRF) which recently hosted their Reaching for the Cure Event. The 19th Annual 10K Run, 5K Run/Walk, 1K Kids' Fun Run & Bike Tour event raised over $565,000 in total contributions. It is recognized as one of OC's favorite weekend family events. It was held at Irvine Valley College on March 25th and 26th and was attended by over 5,000 people. Powerstone, for the sixth year in a row, raised the largest amount for a Corporate Champion team. " Team Powerstone is very excited to be a part of this great event. And, this year thanks in large part to our Diamond Sponsors, we broke our own record," says Rene' Decker, CEO of Powerstone, who adds: "Once again I'd like to thank our team lead by Kendrah Kay for the outstanding job she does in getting sponsors and raising the level of excitement for the event. I honestly feel like this makes a big difference in reaching the cure. We're very proud to be part of such a great cause." Jeri Wilson, PCRF Executive Director had this to say: "We consider Powerstone to be a leader in the fight to find a cure for pediatric cancer.  They provide volunteer team members as well as financial support and a true spirit of giving that sets the bar very high." She added: "At Reaching for the Cure Run and Ride, Team Powerstone makes curing cancer fun, while raising money year round with their company and vendors. These children need our help, they may only be 1% of the oncology population, but they are 100% of our future. Let's give these families hope, so that their children can live out their dreams." This year Powerstone is excited to name the following Diamond Sponsors who donated a minimum of $4,250 and include Antis Roofing & Waterproofing, Animal Pest Management, Nordic Security Services, James LeCourt Plumbing, O'Connell Landscape Maintenance, Park West Landscape Management, Fontaine Weatherproofing, and The Perry Law Firm. About PCRF The Pediatric Cancer Research Foundation holds special events throughout the year. For more information call the PCRF office at 949-859-6312 or visit http://www.pcrf-kids.org. Since its founding in 1982, PCRF has partnered with businesses, foundations, and individuals and has raised over $30 million toward the ultimate goal of ending pediatric cancers. About Powerstone Known for its exceptional service, Powerstone is a recognized leader and one of the largest property management firms in Southern California. Since 1993 Powerstone has served the CID industry (common interest development) with integrity, professionalism and expertise, including three on-staff CPA's. From professional business planning, governance, and community management, to modern yet easy to use customized websites and on-line services, Powerstone provides homeowner associations complete and unparalleled service including customized Community Planning. Powerstone believes that every association deserves the chance to attain their vision for their property and that's why we created the best combination of people and technology to not only better serve, but also to better achieve. For more information, go to http://www.Powerstonepm.com


Those trusts are formed under a law allowing companies with asbestos liability to emerge from a bankruptcy process solvent while creating trusts to pay currents and estimated victims. The AGs are concerned that negligent management of the trusts is cutting the amounts available to help victims, a disproportionate number of whom are veterans, and may not be repaying health care costs. Those victims may be unaware of possible claw-back actions coming down the pike. The multi-state investigation comes on the heels of the "Garlock" case in North Carolina when a federal judge disclosed that evidence had been suppressed in all 15 cases where he had allowed specific discovery. Both the CID and the Utah lawsuit make clear links to the Garlock case and represent the first law enforcement action on the judge's findings. Statement from Sara Warner, a founding member and spokesperson for the ADVWG: "Every day we see health care costs driving national debates, and the strong showing of 13 AGs demonstrates just how concerning this situation is. But sadly, this is not an issue that only pertains to just these states. This is a deep seeded problem and the potential corruption must be fleshed out, and that requires coordination with more states and even federal involvement. "The core issue is transparency. It is due to a lack of transparency that nobody knows how deep or how costly the fraud might run. Transparent compliance with public quarterly filings is the only answer. If publicly traded companies face similar transparency, why not the trusts? "This seems a step toward exactly what we feared might happen; asbestos victims are being implicated in the complexities of potential fraud and many of them are going to be military veterans, and we simply must get in front of this potential crisis." The Asbestos Double-Victims Workgroup was formed to explore the idea that current – and future – changes in the asbestos litigation world are going to impact a very specific group of victims of asbestos disease – those who have already gone through the legal system. These individuals and their families are already victims of America's longest-running personal injury challenge; now they might become victims of the very legal system they turned to for justice and they may find themselves under scrutiny and even financial liability for actions taken years ago under advice of their legal representatives. Background on the Asbestos Double-Victims Workgroup can also be found on our website and a recent article by Sara Warner published on the The Huffington Post. On March 7, 2017, 13 attorneys general filed a civil lawsuit in Utah to investigate into whether several large national asbestos trusts reimbursed Medicaid and other medical providers when they received settlements and compensated victims. This lawsuit comes after the trusts failed to comply with a "civil investigation demand" letter  issued in December 2016. The letter states the following: "…As chief legal officers for our respective states, we are concerned about potential abuse of the asbestos trusts. Plaintiffs' attorneys are using the trusts to obtain significant monetary recovery for claims, even where they would fail in the tort system. The abuse injures our states by improperly draining the trust assets, precluding future legitimate claimants from relying on the trust, and leaving states with the high cost associated with asbestos-related disease....This evidence suggests that the trusts are not sufficiently rigorous in scrutinizing their claims. This lack of oversight also raises questions as to whether the trusts and claimants attorneys are ensuring that state medical assistance programs are being reimbursed once the trust pays claimants who have also received compensation from those programs…" To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/advwg-applauds-the-13-states-investigating-asbestos-bankruptcy-trusts-calls-on-remaining-states-and-federal-officials-to-join-300452349.html


News Article | February 21, 2017
Site: www.businesswire.com

MINNEAPOLIS--(BUSINESS WIRE)--DLR Group today announced the acquisition of Minneapolis-based interior design firm Studio Hive. Founded in 2003 by Janice Carleen Linster, FASID; Shari Bjork, LEED AP; and Shawn Gaither, AIA, Studio Hive is consistently ranked as one of the leading interior design firms in the Twin Cities. Studio Hive is a recognized leader in the design of workplace, sports, and higher education environments, for clients including Gray Plant Mooty, Fox Rothschild, the University of Minnesota, UCare, as well as interior design at many of the collegiate and professional sports stadiums in the Twin Cities. Studio Hive’s 14 design professionals will relocate to DLR Group’s Renaissance Square location at 520 Nicollet Mall by early April. With the addition of Studio Hive, DLR Group will have 80 employee-owners in Minneapolis. “A common culture is instrumental when bringing two firms together. Studio Hive and DLR Group share a commitment to design excellence and our collective client base will be well served,” said DLR Group CEO Griff Davenport, AIA. “Studio Hive is recognized locally and nationally as an innovator in the practice of workplace interiors and this elevates the depth and expertise of our Workplace Studio both in Minneapolis and nationally. Linster will head the Minneapolis Workplace Studio. She will collaborate with DLR Group Workplace Leader Cassandra Griep, CID, IIDA, and with Bjork and Gaither, to meet the needs of clients in the Twin Cities. Linster also will join the DLR Group Global Workplace Studio, led by Angela Castleton. Our clients have operations and interests on the ground in markets across the country,” said Castleton. “The addition of Janice, Shari, and Shawn adds depth to our local and global practices, and enhances the strategic thinking and design expertise we can deploy to meet the needs of our clients anywhere at any time.” “The opportunities available to our staff for personal and professional growth at DLR Group are virtually limitless,” said Linster. “Cassandra and her team have built an innovative Workplace Studio. We are excited to join forces and collaborate to grow an award-winning Workplace Studio in the Twin Cities and across the country with DLR Group.” Gaither will join the firm’s Higher Education Studio, bringing more than 15 years of experience working on college campuses, including design at the University of Minnesota. “Janice, Shari, Shawn and the entire Studio Hive team add proven and experienced design talent in Minneapolis. This will positively impact the mentoring and professional growth of the entire office,” said Davenport. “I am also very excited to offer ownership and a wide range of new design and career opportunities – new market types, services, and geographies – for Studio Hive design professionals to explore at DLR Group.” DLR Group is a 100 percent employee-owned firm and all Studio Hive design professionals will have the opportunity to purchase stock and invest in the future of DLR Group. DLR Group is an integrated design firm delivering architecture, engineering, interiors, planning, and building optimization for new construction, renovation, and adaptive reuse. Our promise is to elevate the human experience through design. This promise inspires sustainable design for a diverse group of public and private sector clients; local communities; and our planet. DLR Group is 100 percent employee-owned and fully supports the initiatives and goals of the 2030 Challenge, and is an initial signatory to the China Accord and the AIA 2030 Commitment. Our view of the world.


HOUSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of updated clinical results from its multicenter BP-004 clinical trial of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. Results on 73 patients with more than six months of follow-up demonstrated that the use of BPX-501 following an alpha/beta-depleted, haploidentical hematopoietic stem cell transplant (haplo-HSCT) resulted in rapid immune recovery in patients with inherited blood disorders and hematological cancers. “The results from our BPX-501 clinical program continue to demonstrate positive and consistent results across multiple centers and diseases, underscoring its potential to address the needs of a wide range of pediatric patients who lack access to a suitable matched donor,” commented Rick Fair, President and CEO of Bellicum Pharmaceuticals. “The data reported today, including incidences of GvHD- and disease-free outcomes in children with blood cancers and genetic diseases, compare favorably to historical outcomes in patients receiving a matched unrelated donor (MUD) transplant, the comparative population for our ongoing registration trial in Europe.” Updated Results of BP-004 Study To date, 122 pediatric patients have undergone treatment with BPX-501. Investigators reported on 91 patients with 100 days of follow-up, 73 patients with six months, and 45 patients with more than one year of follow-up. Genetic blood diseases (n=54) include SCID (Severe Combined Immune Deficiency) (n=11), thalassemia major (n=8), Wiskott-Aldrich syndrome (n=6), sickle cell disease (n=3), and several others. Hematological cancers (n=37) include ALL (acute lymphoblastic leukemia) (n=22), AML (acute myeloid leukemia) (n=13), and others. Patients receiving BPX-501 following a haplo-HSCT demonstrated rapid immune reconstitution by month six, including full recovery and normalization of T-cells, B-cells and immunoglobulins. Cumulative incidence of treatment-related mortality remains very low in the BP-004 study, with six-month and one-year survival rates of 98.4 percent and 97.2 percent, respectively, and no mortality associated with use of BPX-501 or rimiducid. Of 73 patients with more than six months of follow-up, 22 percent had acute Grade 1-2 GvHD, 2.7 percent had Grade 3, and there were no cases of Grade 4 GvHD. In the BP-004 study, rimiducid was used on six patients experiencing GvHD that was not controlled by the use of standard treatments. In all five cases of uncontrolled acute GvHD, the administration of rimiducid rapidly resolved the symptoms.  As previously reported, there was one case of severe chronic GvHD attributed to cells from the donor graft, and unrelated to BPX-501, in a malignant patient that did not resolve with administration of rimiducid. The poster presentation can be accessed in the Events and Presentations section of the Bellicum website. About BPX-501 BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable GvHD risk. The ongoing BP-004 clinical study of BPX-501 is being conducted at transplant centers in the U.S. and Europe. About the BMT Tandem Meetings The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT). Attended by investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators, and allied health professional attendees, the scientific program addresses the most timely issues in hematopoietic cell transplantation. About Bellicum Pharmaceuticals Bellicum is a leader in developing novel, controllable cellular immunotherapies for cancers and for orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid and CaspaCIDe; the effectiveness of rimiducid and of CaspaCIDe; the effectiveness of BPX-501 and its possible range of application and potential curative effects and safety in the treatment of diseases including as compared to other treatment options and competitive therapies; the timing and success of our BP-004 clinical trial, including the rate and progress of enrollment; and, the timing of regulatory filings for BPX-501 and for rimiducid. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Receive press releases from Alex Wan for Atlanta: By Email Alex Wan Again Gains Support of National Victory Fund in Race for Atlanta City Council President Atlanta City Councilmember Alex Wan, who is seeking the second-highest elected position in Atlanta government, Atlanta City Council President, has been endorsed by Gay & Lesbian Victory Fund. www.AlexWanForAtlanta.com Atlanta, GA, February 16, 2017 --( “We were proud to endorse Alex in 2009 and 2013, and are thrilled to endorse him again today,” says Victory Fund President & CEO Aisha Moodie-Mills. “Alex has been a staunch and vocal supporter of the District’s diverse neighborhoods, and embraced his role on the City Council with an admirable collaborative leadership style. His service and leadership during a time of great political change for LGBT people is critical – and Atlanta will be a better city with Alex leading the City Council.” “I am honored by the support of Victory Fund,” says Wan, whose professional experience includes the private, public, non-profit and higher-education sectors, is in the fourth year of his second term representing District 6 on City Council. “Victory Fund’s candidate training and support played an important part in my public service journey and helped lead to my initial decision to run for office and, now, as I seek to continue my service. I look forward to continuing to move away from politics as usual, with genuinely collaborative engagement between all of the city’s stakeholders.” In his bid for Council President, Wan says he will continue to leverage deep roots in the community, long-time civic leadership, business acumen and his record during seven years at city hall. “I’m eager to continue working on tough issues like transportation, infrastructure, affordable housing, operational efficiency, sound fiscal stewardship, public safety, individual and collective economic prosperity, and quality of life,” he says. Wan was first elected to the City Council District 6 post in 2009 and easily earned a second term in 2013 with 76 percent of the vote, both times garnering a broad base of support. He is the first Asian American and first openly gay man to serve on Atlanta City Council. He is (currently) Director of Development and Alumni Relations at Emory University. Raised in Atlanta and a Morningside homeowner for over 20 years, Wan was perhaps best known before his Council win for long-time community involvement, including service on the Invest Atlanta (formerly Atlanta Development Authority) Board and founding For the Kid in All of Us, an all-volunteer non-profit serving children in need. He currently serves on Boards of Directors for the Piedmont Park Conservancy, the Little Five Points Community Improvement District (CID), and the Olmsted Linear Park Association. He holds a Bachelor’s in Industrial Engineering from Georgia Tech, a Finance MBA from Wharton Business School, and has completed educational programs at Dartmouth and Harvard. The Atlanta City Council President is elected city wide, presiding at all Council meetings and voting in the event of a tie. The president of the Council also appoints chairs and members of the various committees. Council President also serves as vice mayor, acting for the mayor in certain instances. The Atlanta City Council President is elected for a four-year term, with the election to be held in November 2017, taking office in January 2018. The current City Council President is running for mayor. For more information about Wan and his campaign: www.AlexWanForAtlanta.com. Atlanta, GA, February 16, 2017 --( PR.com )-- Atlanta City Councilmember Alex Wan, who is seeking the second-highest elected position in Atlanta government, Atlanta City Council President, has been endorsed by Gay & Lesbian Victory Fund. Victory Fund (www.VictoryFund.org) is the only national organization dedicated to increasing the number of openly lesbian, gay, bisexual and transgender elected officials at all levels of government.“We were proud to endorse Alex in 2009 and 2013, and are thrilled to endorse him again today,” says Victory Fund President & CEO Aisha Moodie-Mills. “Alex has been a staunch and vocal supporter of the District’s diverse neighborhoods, and embraced his role on the City Council with an admirable collaborative leadership style. His service and leadership during a time of great political change for LGBT people is critical – and Atlanta will be a better city with Alex leading the City Council.”“I am honored by the support of Victory Fund,” says Wan, whose professional experience includes the private, public, non-profit and higher-education sectors, is in the fourth year of his second term representing District 6 on City Council. “Victory Fund’s candidate training and support played an important part in my public service journey and helped lead to my initial decision to run for office and, now, as I seek to continue my service. I look forward to continuing to move away from politics as usual, with genuinely collaborative engagement between all of the city’s stakeholders.”In his bid for Council President, Wan says he will continue to leverage deep roots in the community, long-time civic leadership, business acumen and his record during seven years at city hall. “I’m eager to continue working on tough issues like transportation, infrastructure, affordable housing, operational efficiency, sound fiscal stewardship, public safety, individual and collective economic prosperity, and quality of life,” he says.Wan was first elected to the City Council District 6 post in 2009 and easily earned a second term in 2013 with 76 percent of the vote, both times garnering a broad base of support. He is the first Asian American and first openly gay man to serve on Atlanta City Council. He is (currently) Director of Development and Alumni Relations at Emory University.Raised in Atlanta and a Morningside homeowner for over 20 years, Wan was perhaps best known before his Council win for long-time community involvement, including service on the Invest Atlanta (formerly Atlanta Development Authority) Board and founding For the Kid in All of Us, an all-volunteer non-profit serving children in need. He currently serves on Boards of Directors for the Piedmont Park Conservancy, the Little Five Points Community Improvement District (CID), and the Olmsted Linear Park Association.He holds a Bachelor’s in Industrial Engineering from Georgia Tech, a Finance MBA from Wharton Business School, and has completed educational programs at Dartmouth and Harvard.The Atlanta City Council President is elected city wide, presiding at all Council meetings and voting in the event of a tie. The president of the Council also appoints chairs and members of the various committees. Council President also serves as vice mayor, acting for the mayor in certain instances. The Atlanta City Council President is elected for a four-year term, with the election to be held in November 2017, taking office in January 2018. The current City Council President is running for mayor.For more information about Wan and his campaign: www.AlexWanForAtlanta.com. Click here to view the list of recent Press Releases from Alex Wan for Atlanta


PARIS--(BUSINESS WIRE)--PathoQuest, a biotechnology company spun out from Institut Pasteur, announced today the on-line publication of results from the PATHOQUEST-1 study. The full manuscript, titled Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study, is available in Clinical Microbiology and Infection. PATHOQUEST-1 (NCT02007642) is an observational proof-of-concept study conducted in 2 reference hospitals -Necker-Enfants Malades and Européen-Georges Pompidou hospitals- (Paris, France). It enrolled 101 immunocompromised patients suspected of infection, and compared the performance of PathoQuest’s NGS-based metagenomics test and the conventional diagnostic pipeline to identify pathogens. PATHOQUEST-1 was run with a prototype version of the CE-IVD iDTECT Blood™ test. The 3 key components of the test -i.e. sample preparation, sequencing and data analysis- have been improved to reach the level of performance and validation required for CE marking. Specific steps of the test process have been patented or copyrighted and are proprietary. “This study demonstrates that the metagenomic test identified a relevant pathogen in more patients in a difficult-to-diagnose population than the conventional pipeline,” said Marc Eloit, PhD, Pathogen Discovery Laboratory at Institut Pasteur, Paris, France, a study investigator and founder and scientific advisor for PathoQuest. “These data underscore the potential of NGS to improve detection and identification of pathogens in routine diagnostic testing of biological samples including blood which is technically challenging.” “With the broader availability of sequencing platforms in clinical microbiology laboratories, metagenomics-based testing will increase our chances of identifying pathogens in infected patients and allow a better management of infectious diseases, especially in immunocompromised patients where the current diagnostic pipeline frequently fails to identify a responsible pathogen.” added Xavier Nassif, MD, PhD, Head of the Clinical Microbiology Laboratory, Necker-Enfants Malades Hospital, Paris, France, and a study investigator. “These study results should pave the way for such developments”. Immunocompromised patients have an impaired or weakened immune system resulting in an increased susceptibility to infection and reduced ability to efficiently respond to such situations. This inability to fight infections can be caused by a number of diseases (such as cancer or leukemia), or drugs (such as anti-cancer therapies or long term immune-suppressants used to prevent organ rejection). Prevalence of these conditions is increasing. Identifying the causative pathogen(s) in immunocompromised patients suspected of infection can be challenging. For instance, only 20 to 30% of blood cultures, the conventional diagnostic test in this clinical situation, are positive for a pathogen in patients developing febrile neutropenia following chemotherapy or stem cell transplantation (1,2,3). In most other cases, the infection remains of unknown origin, leading to the systematic use of broad spectrum instead of targeted antibiotics. Moreover, these patients are more susceptible to viruses or other microorganisms which have limited or no pathogenicity for non-immunocompromised subjects. Many also receive prophylactic or recurrent courses of antibiotics, making their pathogens difficult to grow in the lab. 1 Gyamarti et al, Scientific Reports, 2016 2 Freifeld et al, CID 2011 3 Gea-Banacloche, Hematology Am Soc Hematol Educ Program. 2013 PathoQuest, a spin out of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving pathogen detection in biological samples that overcomes the current limitation associated with pathogen detection. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The company’s solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens. PathoQuest has developed iDTECT™ Blood Test, the first and only clinical CE IVD metagenomic test in infectious disease. Using a single blood sample, the test provides clinicians and microbiologists with an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test should improve antibiotic stewardship and lead to better patient care through precision medicine. Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure production of biologics like vaccines and recombinant proteins. PathoQuest’s solution is currently being utilized by several major biopharma companies for this purpose. To learn more about PathoQuest, visit www.pathoquest.com


News Article | January 13, 2017
Site: www.techtimes.com

Exxon Mobil is under investigations by the federal authorities due to an alleged non-disclosure of its climate change research containing environmental risks. A recent judiciary decision ordered the company to hand over 40 years of research on the impact of fossil fuels on climate change. Attorney General Maura Healey filed a Civil Investigative Demand (CID) to collect the said documents from Exxon Mobil, which the court later on favored. With the decision, the government and the public will finally discover what the company knew and whether or not they have been hiding the truth. Superior Court Judge Heidi E. Brieger from Massachusetts issued a 14-page order favoring the state law that grants the government to investigate if the company lied and mislead the public about the risks of fossil fuels and its contribution to climate change. The order requires Exxon Mobil to disclose 40-years' worth of studies and research. Environmentalists argue that the company is already aware of the risks posed by fossil fuels, but they concealed the information to continue running the business and at the same time misleading the public. The company filed a motion to set aside the CID filed by Healey. In the company's defense, they accused Healey of being biased for pressing an investigation. However, the judge backed up the attorney general's petition. "Exxon also argues that the CID is politically motivated...As discussed above, however, the court finds that the attorney general has assayed sufficient grounds - her concerns about Exxon's possible misinterpretation to Massachusetts consumers - upon which to issue the CID," Judge Heidi E. Brieger said in the order. "In light of these concerns, the court concludes that Exxon has not met its burden of showing that the attorney general is acting arbitrarily or capriciously toward it." Exxon Mobil is required to hand over the documents to Healey based on the order released last Wednesday, Jan. 11. LA Times previously reported that the company has already been doing climate change research since the 1980s and 1990s. An Exxon spokesperson said in an interview that the company is already "reviewing the decision to determine next steps." Last March, the United States Securities and Exchange Commission ordered Exxon to uphold shareholders' vote and to outline its anti-climate change strategy. Exxon had already received a subpoena filed by the U.S. Virgin Islands Attorney General Claude Earl Walker. Sadly, Exxon is not the only company who knew about climate change since the early 1970s, a report claims. The timely decision was issued when the former Exxon chief executive Rex Tillerson faced a Senate hearing to confirm his nomination as President-elect Donald Trump's secretary of state. During the hearing, he was asked about climate change but refused to divulge information about the company's knowledge on the issue. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.

Loading CID collaborators
Loading CID collaborators